Skip to content
News Release:
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
New Blog:
Explore an example of agentic rational design using Anthropic’s Claude in “Less is More: Refactoring the CAR Signaling Domain”
Announcement:
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics for Metabolic Diseases
Announcement:
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
Menu
Close
Generative Biology®
The Generate Platform™
Pipeline
About Us
Careers
Media Center
Investors
LinkedIn
X
YouTube
Presentations & Publications
A phase 1 study of GB-4362 ESMO Madrid 2026
10.23.2026
Download as PDF
